A case of progressive pulmonary interstitial fibrosis following adjuvant lomustine (CCNU)-5-fluorouracil therapy for a colon carcinoma is reported. A close relationship between lomustine assumption and lung damage seems to emerge from the clinical, radiologic and histologic findings presented. On the basis of this experience and previous available data from literature, pulmonary toxicity must be regarded as a possible adverse effect of lomustine therapy.
Get full access to this article
View all access options for this article.
References
1.
AhlgrenJ.D., SmithF.P., KerwinD.M., SikicB., WeinerJ.H., ScheinP.S.: Interstitial pulmonary toxicity as a complication of chlorozotocin chemotherapy.Cancer Treat. Rep., 65: 223–229, 1981.
2.
AroninP.A., MahaleyM.S., RudnickS.A., DudkaL., DonohueJ.F., SelkerR.G., MooreP.: Prediction of BCNU pulmonary toxicity in patients with malignant gliomas. An assessment of risk factors.N. Engl. J. Med., 303: 183–188, 1980.
3.
BatistG., AndrewsJ.L.: Pulmonary toxicity of antineoplastic drugs.JAMA, 246: 1449–1453, 1981.
4.
CordonnierC., VernantJ.P., MitalP., LangeF., BernaudinJ.F., RochantH.: Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.Cancer, 51: 1814–1818, 1983.
5.
DentR.G.: Fatal pulmonary toxic effects of lomustine.Thorax, 37: 627–629, 1982.
6.
De VitaV.T., CarboneP.P., OwensA.H., GoldG.L., KrantM.J., EdmonsonJ.: Clinical trials with 1,3-bis(2 - chloroethyl)-1-nitrosourea, NSC - 409962.Cancer Res., 25: 1876–1881, 1965.
7.
De VitaV.T., HellmanS., RosenbergS.A. (Editors): Cancer. Principles and Practice of Oncology.J.B. Lippincott Co., Philadelphia-Toronto, 1982.
8.
LeeW., MooreR.P., WamplerG.L.: Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy.Cancer Treat. Rep., 62: 1355–1358, 1978.
9.
RyanB.R., WaltersT.R.: Pulmonary fibrosis: a complication of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.Cancer, 48: 909–911, 1981.
